Singapore Medical Group in the pink of health
The Catalist-listed company today has a market capitalisation of over S$200 million, and has been profitable since FY2016.
Add BT as a preferred source
THESE days Singapore Medical Group (SMG) barely resembles the once ailing entity that it was.
In 2013, the Catalist-listed group faced significant headwinds and losses due to the changing medical landscape in Singapore: declining medical tourism, changing economics of healthcare and growing trend of consolidation of medical practices.
The same year, SMG chief executive officer Dr Beng Teck Liang and his partners, including SMG chairman Tony Tan Choon Keat, a founder of Singapore's Parkway Holdings, acquired a controlling shareholding of SMG and set out a three-year plan to rebuild the business.
TRENDING NOW
Tiger Brokers, Moomoo, Longbridge Singapore units ‘financially independent’ amid China crackdown: MAS
Yeo’s, Tiger Beer and now Gardenia – flight of food manufacturing from Singapore might be just as planned
Johor property old hand KSL readies family handover amid market boom
As India and China surge ahead with nuclear energy, all eyes on Asean’s next move
